Last reviewed · How we verify
metformin, rosiglitazone
Metformin and rosiglitazone, marketed by University Medical Centre Ljubljana, are established treatments in the diabetes market. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity. The primary risk is the lack of recent key trial results to support ongoing efficacy and safety claims.
At a glance
| Generic name | metformin, rosiglitazone |
|---|---|
| Sponsor | University Medical Centre Ljubljana |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) (PHASE3)
- Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients. (PHASE2, PHASE3)
- Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study
- Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes (PHASE3)
- Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin, rosiglitazone CI brief — competitive landscape report
- metformin, rosiglitazone updates RSS · CI watch RSS
- University Medical Centre Ljubljana portfolio CI